Iconix - NewsCenter

2008	Society of Toxicology 2008 Annual Meeting Mar 16, 2008 , Seattle, WA Posters Monday, March 17, 2008 9:00am-12:30pm, Poster Board #518, Abstract #250 Generation and Validation of Multi-gene Validated Biomarkers for Prediction and Diagnosis of Bile Duct Hyperplasia in Rats, Jeffy BD, Blomme E (Abbott) and Yang Y (Abbott). 9:00am-12:30pm, Poster Board #519, Abstract #251 Third-party Biomarker Validation and Hypothesis Generation in a Very Large Toxicogenomic Database, Gollub J, Jeffy B, Pearson C, Halbert DN, and Roter AH. Wednesday, March 19, 2008 9:00am-12:30pm, Poster Board #515, Abstract #1578 Toxicogenomic Comparison of Rat Liver and Primary Hepatocytes Following Compound Exposure, Yang A, Pearson C, Gollub J, Vladimirova A. 1:00pm-4:30pm, Poster Board #629, Abstract #1931 Identification and Characterization of Novel AhR Ligands across Species, Sorrentino C (UC Davis), Hu W, Fielden M (Roche) and Denison MS (EPA). http://www.toxicology.org/ai/meet/am2008/index.asp
2007	Society of Toxicology 2007 Annual Meeting Mar 26, 2007 , Charlotte, NC USA Platform Session Wednesday, March 28, 2007 9:24 AM - 9:48 AM, Room 207C (Charlotte Convention Center) Evaluation Of Cardiotoxicity Potential Of The Cancer Therapeutic Agent Gleevec Based On Gene Expression Data In Rat, Vladimirova A, Halbert DN and Fielden M. Posters Monday, March 26, 2007 9:30am-12:30pm, Poster Number 257-432 A Chemogenomic Analysis Of The Drug-Drug Interaction Between Statins And Fibrates, Lee MD, Ganter B, Jarnagin K and Halbert DN. 1pm-4:30pm, Poster Number 456-403 Toxicogenomics Analysis Correlates Attenuation Of Nrf2 Function With Renal Toxicity In The Rat, Gong L, Hu W, Halbert DN and Lee MD. 1pm-4:30pm, Poster Number 459-406 Toxicogenomic Investigation Of Mechanisms And Markers Of Nephrotoxicity By Incorporating Laser Capture Microdissection And A Contextual Microarray Database, Yang AH1, Ramiro-Ibanez F2, Fuentealba C2, Vladimirova A1 and Jessen B2. Tuesday, March 27, 2007 1pm-4:30pm, Poster Number 1024-129 Human PBMCs As An In Vitro Model For Identifying Human Biomarkers To Predict Mechanisms Of Compound Induced Toxicity, Patil NS, Brady L, Brown S, Faravashi N, Eynon B, Gollub J, Nair R, Fujimoto S, Day GJ, Halbert DN. Thursday, March 29, 2007 8:30am-12:00pm, Poster number: 1945-161 Gene Expression-Based Prediction And Mechanistic Assessment Of Non-Genotoxic Chemical-Induced Hepatocarcinogenicity, Fielden M, Brennan R., Gollub J. http://www.toxicology.org/ai/meet/am2007/index.asp
2006	Society of Toxicology 2006 Annual Meeting Mar 5, 2006 , San Diego, CA USA Platform Sessions Tuesday, March 07, 2006 9:00 am-12:00 pm, Rm 15A, Biomarkers: Identification and Application 9:00-9:22 am, 784. Validation of Putative Biomarkers for the Early Prediction of Non-Genotoxic Hepatocarcinogenesis and Comparison to Drug Signatures, M. R. Fielden et al. 10:06-10:28 am, 787. Cyp1a1 Induction and Aryl Hydrocarbon Receptor Activation: Death Penalty for Preclinical Drug Candidate? C. Sorrentino (UC Davis) et al. 1:30-3:45 pm, Rm 11A, Affymetrix Workshop, Removing the Barriers to Widespread Adoption of Toxicogenomics in Drug Discovery, J. Retief. Wednesday, March 8, 2006 1:30-4:30pm, Rm15A, Bioinformatics and Biological Modeling 2:58-3:20 pm, 1889. A Small Number of Genes are Sufficient to Classify a Large Number of Unique Toxicological and Pharmacological End-points Using Gene Expression, G. Natsoulis et al. 1:30-4:30 pm, Rm 2, Predicting Compound Toxicity 3:20-3:42 pm, 1907. Human PBMCs as an In Vitro Model for Predicting Compound Toxicity, N. Patil et al. Thursday, March 9, 2006 9:00-am-12:00 pm, Rm 8, Application of Genomics to Evaluating Mechanisms of Genotoxicity and Carcinogenicity, R. J. Brennan (symposium co-chair) 10:20-10:55 am, 2219. Development and application to drug discovery of gene expression biomarkers for genotoxicants and carcinogens, R. J. Brennan. Posters Monday, March 06, 2006 9:30am-12:00 pm, Exhibit Hall, Biomarkers 169. Hepatic transcriptome differentiates a selective PDE4 inhibitor and identifies a possible mechanism of acute phase response (APR) due to loss of intestinal permeability, R. Eyre (ICOS) et al. 182. Blood as a Toxicogenomic tissue, C. Pearson et. al. Tuesday, March 07, 2006 9:00am-12:00 pm, Exhibit Hall, Bioinformatics 987. Motif Technology and Applications in Understanding the Mechanism of Drug Toxicity and Action, A.Vladimirova et al. 993. Genomic effects of diet restriction and drug-induced hepatotoxicity in male rat liver, S. Burel (Neucrocrine) et al. 1:30-4:30 pm, Exhibit Hall, Gene Regulation I 1358. Relationship between drug-induced iNOS-2 gene induction and p450 gene repression: mechanistic differences among drug classes, B. Ganter R. D. Snyder (Schering-Plough) et al. Thursday, March 09, 2006 9:00am-12:00 pm, Rm 6ABCF, Liver III 2392. Characterization of compound-induced hepatotoxicity using gene expression profiling in rat primary hepatocytes, G. Day, T. P. Ryan (Lilly) et. al. 2337. Toxicogenomic Study of Triazole Fungicides, W. Hu, D. Dix (EPA) et al. http://www.toxicology.org/ai/meet/am2006/index.asp
2005	CBI's “Predicting Drug Safety and Risk” Conference May 23, 2005 , Boston, MA Richard Brennan, Ph.D, “Assess electrophysiological effects of compounds early in drug development to save time and costs” Donald N. Halbert, Ph.D, "Application of Toxicogenomics to Increase Efficiency of Drug Discovery" http://www.cbinet.com/show_conference.cfm?confCode=HB533
	Society of Toxicolgy 2005 Annual Meeting Mar 6, 2005 , New Orleans, LA TALKS: Large-scale gene expression profiling in rats identifies many novel Cyp1a1 inducers and Ah receptor ligands Wenyue Hu, Mark R. Fielden, David Baston, Bin Zhao, Jessica Bohonowych, Anatoly Soshilov, Danica DeGroot, Claudio Sorrentino, Michael Denison and Kyle Kolaja Cytochrome P450: Monday, March 7, AM Beyond liver toxicogenomics: cardiac and renal signatures of pharmacology and toxicology Kyle Kolaja, Session Chair Gene Expression-based Biomarkers in Non-Hepatic Tissues: Tuesday March 8, AM Support vector machine algorithm for the prediction of gene function using a large chemogenomic reference database Georges Natsoulis, Mark R. Fielden, Wendy Hu and Kyle Kolaja Bioinformatics: Applications to Toxicology, Wednesday March 9, PM POSTERS: The biology of drug signatures Cecelia Pearson, Richard Brennan, Mark Fielden, Brigitte Ganter, Wendy Hu, Stuart Tugendreich, Antoaneta Vladimirova and Kyle Kolaja Gene Expression I: Monday, March 7, 9:30AM–12:30PM Biomarkers that characterize fibrosis and bile duct hyperplasia Antoaneta Vladimirova, Richard Brennan, Mark Fielden, Kyle Kolaja and Cecelia Pearson Biomarkers: Monday, March 7, 1:30–4:30PM Cross-tissue biomarkers that predict and characterize the acute phase response Stuart Tugendreich Biomarkers: Monday, March 7, 1:30–4:30PM The molecular basis for the prediction of future renal tubular injury following short-term compound treatment with Drug Signatures Mark Fielden, George Natsoulis and Kyle Kolaja Biomarkers: Monday, March 7, 1:30–4:30PM Multi-tissue characterization of rhabdomyolysis for the high profile failure cerivastatin B. Ganter and Kyle Kolaja Biomarkers: March 7, 1:30–4:30PM A rat heart gene-expression signature predictive of HERG potassium channel binding Xie Xu, Richard J. Brennan, Gene Napolitano and Kyle Kolaja Cardiovascular Disease I – Gene Expression: Wednesday, March 9, 1:30–4:30PM WORKSHOP: Applying Chemo- and Toxicogenomicsto Prioritize Preclinical Candidates Mark Fielden, Richard Brennan March 9, 12:15-1:15PM
2004	The Impact of Chemogenomics on Biomarker Development in Discovery and the Clinic May 20, 2004 , Philadelphia, PA A free seminar sponsored by Iconix and MDS Pharma Services on the application of genomics to the discovery of biomarkers for toxicity and mechanism-of-action by leading pharmaceutical companies. http://www.mdsps.com/events/bostonphiladelphia2004.htm
	The Impact of Chemogenomics on Biomarker Development in Discovery and the Clinic May 18, 2004 , Boston, MA A free seminar sponsored by Iconix and MDS Pharma Services on the application of genomics to the discovery of biomarkers for toxicity and mechanism-of-action by leading pharmaceutical companies. http://www.mdsps.com/events/bostonphiladelphia2004.htm
	Keystone Symposium: New Advances in Drug Discovery Mar 24, 2004 , Keystone, CO Leslie J. Browne, COO, Iconix : Removing Barriers to Efficient Drug Discovery through Chemogenomics 5-7 PM in Red Cloud Peak room http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=707
	Society of Toxicology Annual Meeting Mar 21, 2004 , Baltimore, Maryland Susanne Baumhueter, Iconix Pharmaceuticals, Classifying Chemical Induced Liver Pathology Using Gene Expression Profiling In Vitro in Primary Hepatocytes. Platform, Tue, Mar 23 at 9:50 AM in Room 317 Donna Dambach, Bristol-Myers Squibb, in collaboration with Iconix Pharmaceuticals, Genomic Characterization of Idiopathic and Drug-Induced Dilated and Hypertrophic Cardiomyopathy in the Rat Heart. Platform, Wed, Mar 24 at 10:50 AM in Room 326 Mark Fielden, Drug Signatures Predict Long-Term Development of Renal Tubule Injury Following Short-Term Test Compound Administration in the Rat. Platform, Wed, Mar 24 at 9:10 AM in Room 326 Kurt Jarnagin, Iconix Pharmaceuticals, Biomarker Sets that Characterize Bile Duct Hyperplasia. Poster, Wed, Mar 24 at 9:30 AM in Exhibit Hall Kyle Kolaja, Iconix Pharmaceuticals: The Present and Future of Toxicogenomics in Preclinical Drug Development. Symposium chair and organizer, Tue, Mar 23 at 4:00 PM in Room 307/308 Kyle Kolaja, Iconix Pharmaceuticals, Use of a Large Chemogenomic Database to Facilitate Drug Development. Symposium, Tue, Mar 23 at 4:00 PM in Room 307/308 Kyle Kolaja, Iconix Pharmaceuticals: Gene Expression: Liver. Co-chair, Platform session, Tue, Mar 23 at 9:50 AM in Room 317 Joseph Monforte, Althea Technologies, in collaboration with Iconix Pharmaceuticals, Use of Express Profiling™ to Characterize Gene Expression Biomarker Sets for Liver Toxicity. Platform, Tue, Mar 23 at 9:50 AM in Room 317 Simone Nicholson, Iconix Pharmaceuticals, Hepatic Gene Expression Signatures Identify Multiple Pathways Related to Ah Receptor Activation Following Short- and Long-Term Compound Administration in Rat. Poster, Thu, Mar 25 at 8:30 AM in Rooms 307/308/309/310 Cecelia Pearson, Iconix Pharmaceuticals, Drug Signatures that Predict a Variety of Pathologies. Poster, Tue, Mar 23 at 9:30 AM in Exhibit Hall Stuart Tugendreich, Iconix Pharmaceuticals, Role of Intestinal Permeability in NSAID- and LPS-Induced Acute Phase Response in Rats. Poster, Thu, Mar 25 at 8:30 AM in Rooms 307/308/309/310 http://www.toxicology.org/memberservices/meetings/am2004/
	BIO CEO & Investor Conference: The Early Bird Gets the Worm Feb 24, 2004 , Waldorf Astoria, New York City Jim Neal, Iconix's CEO, will take part in a roundtable discussion on the evolving relationship between biotech and pharma companies and examine the strategies and valuations behind recent biotech-pharma deals. http://www2.bio.org/hermes/ceo/roundtable/
2003	Predictive Toxicology: Improving Lead Selection through Innovative Thinking (Cambridge Healthtech Institute) Nov 19, 2003 , Boston, MA Dr. Kurt Jarnagin, Vice President of Biology and Chemical Genomics, Iconix Pharmaceuticals, Predicting the Toxicity and Mechanism of New Drug Candidates http://www.healthtech.com/2003/tox/index.htm
	Toxicogenomics International Forum (Pharmaceutical Society of Japan) Oct 9, 2003 , Tokyo Dr. Kurt Jarnagin, Vice President of Biology and Chemical Genomics, Iconix Pharmaceuticals, Predicting the Toxicity and Mechanism of New Drug Candidates http://www.nihs.go.jp/tox/tgif/index_e.html
	Chemical Genomics (Cambridge Healthtech Institute) Oct 7, 2003 , Boston, MA David O'Reilly, Chief Business Office, Iconix Pharmaceuticals, Chairman's Remarks, Panel on chemical genomics http://www.genomicsontarget.com/chg2003.asp
	Accelerating Drug Discovery to Development via Cutting Edge ADMET(IBC Life Sciences) Sep 15, 2003 , Boston, MA Leslie J. Browne, Ph.D., COO, Iconix Pharmaceuticals, Applying Chemogenomics to Drug Discovery http://www.lifesciencesinfo.com/admet
	FDA: CDER Advisory Committee for Pharmaceutical Science, Pharmacology Toxicology Subcommittee Jun 10, 2003 , Rockville, MD Kurt Jarnagin, Vice President of Biology and Chemical Genomics Dealing Effectively with Data Quality Issues and Information Content Necessary to Develop a Database http://www.fda.gov/ohrms/dockets/ac/03/agenda/3964A1_Draft.htm
	FDA: CDER Spring 2003 Pharmacology/Toxicology Retreat May 21, 2003 , Rockville, MD Leslie Browne, Ph.D., COO, Iconix Chemogenomics and drug innovation and approval
	Keystone Symposia, New Advances in Drug Discovery Jan 10, 2003 , Park City, UT Kurt Jarnigan New understandings of NSAID activity from chemogenomic profiling
2002	Cambridge Healthtech Institute: Genomics on Target Nov 9, 2002 , Boston, MA David O’Reilly Next Generation Pharmacology with Genomics Tools
	Iconix Pharmaceuticals, MDS Pharma Services and Incyte Genomics: Chemogenomics Seminar: New Approaches to Toxicology and Drug Discovery Oct 29, 2002 , Redwood City, CA Matt Anstett, Senior Application Specialist, Spotfire Data Mining and Visualization of Chemogenomics Data Cynthia Afshari, Associate Director Toxicology, Amgen Inc. The Toxicology and Genomics Interface Gilbert Chu, Professor of Medicine and Biochemistry, Vice President, Biology and Chemical Genomics, Stanford University School of Medicine Transcriptional responses to DNA damage predict toxicity from radiation therapy Alex Elbrecht, Department of Bioinformatics, Merck & Co., Inc. Compound Profiling Using Gene Microarrays Kurt Jarnagin, VP Biology and Chemogenomics, Iconix Pharmaceuticals A New View of Pharmacology and Toxicology Derived from Large-Scale Gene Expression Profiling of Drugs and Biochemicals Roderick V. Jensen, Professor of Physics and Neuroscience, Wesleyan University and Brigham and Women’s Hospital/ Harvard Medical School Shotgun Microarrays: High-throughput Validation of Gene Expression Changes Using Multiple Platforms Kyle L. Kolaja, Ph.D., D.A.B.T., Senior Investigative Toxicologist, Pharmacia Corporation Using toxicogenomic analyses to understand mechanism of toxicity: Case studies of the hepatocarcinogens methapyrilene, clofibrate, and 2-acetylaminofluorene. William D. Pennie, Director, Molecular and Investigative Toxicology, Drug Safety Evaluation, Pfizer, Chairman, ILSI Committee on Application of Genomics and Proteomics to Mechanism-Based Risk Assessment Application of Genomics Technologies in Toxicology and Drug Safety Assessment Alan Roter, Ph.D., Vice President of Informatics, Iconix Pharmaceuticals Process Automation and Informatics Supporting a High Throughput Microarray Data Production Facility Wolfgang Sadée, Professor of Medicine and Pharmacology, Chair, Department of Pharmacology College of Medicine and Public Health, Ohio State University Cellular Transport of Drugs: Nexus Between Drugs and Membrane Transporters Alison Vickers, Ph.D., Associate Director, Head of Functional Validation, Preclinical Safety, Novartis Pharmaceuticals Human Organ Slices for Defining Mechanisms of Toxicity via the Integration of Genomics, Functional Assays and Morphology.
	Iconix Pharmaceuticals, MDS Pharma Services and Incyte Genomics: Chemogenomics Seminar: New Approaches to Toxicology and Drug Discovery Oct 24, 2002 , Cambridge, MA See Previous Entry
	Iconix Pharmaceuticals, MDS Pharma Services and Incyte Genomics: Chemogenomics Seminar: New Approaches to Toxicology and Drug Discovery Oct 22, 2002 , Somertset, NJ See Previous Entry
	Unicom: World Genomics Sep 20, 2002 , Atlantic City, NJ David O’Reilly, panel discussion When and How Will “Omic” Technologies Have a Positive Impact on Pharma’s Output?